Intraday Gainers and Losers

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  29 Sep 2025
 

•   BINI  
   
  +21.09%
•   DFLI  
   
  -9.59%
•   DWTX  
   
  +2.33%
•   IOBT  
   
  -5.13%
•   LAC  
   
  -3.69%

$WOLF captured attention with an eye-popping surge, though this appears to reflect technical factors rather than fundamental transformation. Wolfspeed shares have been under pressure lately, and while investors debate whether the semiconductor company represents a buying opportunity, the extreme volume spike of 5.16 million shares against an average of 38.72 million suggests this may be a short squeeze or data anomaly rather than sustainable momentum.

$POAI rocketed after Predictive Oncology announced private placements totaling $344 million. This massive capital raise provides the oncology-focused company with significant runway to advance its pipeline, and the market clearly views the funding as validation of the technology. The trading volume exploded to 44.23 million shares compared to an average of just 201,590, indicating strong institutional interest in the deal. For a micro-cap biotech, securing this level of financing often represents a transformational moment.

$SCOR jumped following news that Comscore reached a pivotal recapitalization transaction with preferred stockholders and announced board reshaping alongside dividend cuts. The media analytics company appears to be executing a financial restructuring that relieves balance sheet pressure, and investors are betting the transaction provides breathing room for the business to stabilize. Volume surged to 2.32 million shares from a minuscule 6,720 average, suggesting the recapitalization caught the market off guard.

$DWTX climbed after Dogwood Therapeutics secured a royalty-free global license to develop Serpin Pharma's intravenous formulation of SP16 in an all-stock transaction. This licensing deal gives Dogwood exclusive rights to a potentially valuable asset without upfront cash costs, and the biotech community often rewards these types of strategic acquisitions. The volume explosion to nearly 40 million shares from an average of 17,860 reflects the market's enthusiasm for the deal structure.

$MRUS Genmab agreed to acquire Merus for approximately $8 billion in all-cash. The Danish pharmaceutical giant is paying a substantial premium to secure Merus and its breakthrough therapy Petosemtamab for head and neck cancer, which already has breakthrough designation from regulators. This represents exactly the type of biotech exit that investors dream about, and the all-cash nature of the deal removes any execution risk. Trading volume hit 22.05 million shares compared to a 601,540 average as arbitrageurs and momentum traders piled in.

$DFLI Dragonfly Energy showcased technical leadership at The Battery Show North America 2025, with company leaders presenting on US lithium battery manufacturing and hybrid electrification. The five-day winning streak and volume of 126.59 million shares suggests growing investor interest in the domestic battery supply chain story.

$LAC despite renewed buzz around lithium following news that the Trump administration is weighing a stake in the sector. The disconnect between macro enthusiasm and stock performance suggests investors remain skeptical about near-term pricing and demand fundamentals for the white metal.

$VIVK despite securing $23 million in funding to expand its energy business across the Permian and Eagle Ford basins. **$BINI** fell 24.5% to $2.47 on its fifth consecutive down day with no apparent news. **$LRMR** crashed 29.14% to $3.71 despite announcing positive data from an ongoing long-term open-label study of nomlabofusp for Friedreich's ataxia, suggesting the results failed to meet market expectations. **$MTEK** collapsed 51.27% to $2.06 after reporting first-half results that clearly disappointed investors.

$IOBT imploded 78.62% to $0.34 after the FDA recommended against IO Biotech's BLA for its melanoma vaccine, essentially destroying the company near-term value proposition. The volume surge to 25.98 million shares from a 2.86 million average captured the panic as investors rushed for the exits.

$MLTX suffered the day worst performance with an collapse following mixed results from a skin disease trial. MoonLake Immunotherapeutics clearly missed critical efficacy or safety endpoints that the market was banking on, and the 45.52 million share volume spike reflects the complete repricing of the asset. This type of binary event risk is precisely what makes clinical-stage biotechnology so treacherous for investors without deep scientific expertise.

View All Headlines